Protalix Biotherapeutics Inc Earnings

The next earnings date for Protalix Biotherapeutics Inc is November 17, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of Protalix Biotherapeutics Inc Earnings

Report Date	Estimated Earnings Per Share
11/17/2025	$0.07

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

Protalix Biotherapeutics Inc Earnings: Historical

Report Date	Before/After Market	Earnings Per Share	Surprise %
05/08/2025	Before Market	$-0.05	-150.00%
03/12/2025	Before Market	---	---
11/04/2024	Before Market	$0.03	-50.00%
08/14/2024	Before Market	$-0.03	-250.00%
05/10/2024	Before Market	$-0.06	-200.00%
03/14/2024	Before Market	$-0.07	-133.33%
11/06/2023	Before Market	$-0.04	42.86%
08/07/2023	Before Market	$0.21	625.00%
05/04/2023	Before Market	$-0.05	---
02/27/2023	Before Market	$-0.07	53.33%
11/14/2022	Before Market	$-0.07	53.33%
08/15/2022	Before Market	$-0.11	38.89%
05/16/2022	Before Market	$-0.05	-25.00%
03/31/2022	Before Market	$-0.15	-36.36%
11/15/2021	Before Market	$-0.09	25.00%
08/16/2021	Before Market	$-0.25	-212.50%
05/14/2021	Before Market	$-0.14	17.65%
03/30/2021	Before Market	$0.01	112.50%
10/29/2020	Before Market	$-0.14	-75.00%
08/10/2020	Before Market	$-0.13	35.00%
06/01/2020	Before Market	$0.10	133.33%
03/12/2020	Before Market	$0.02	108.00%
11/07/2019	Before Market	$-0.20	42.86%
08/08/2019	Before Market	$-0.50	-66.67%
05/06/2019	Before Market	$-0.50	-100.00%
03/18/2019	Before Market	$-0.37	17.78%
11/07/2018	Before Market	$-1	-150.00%
08/09/2018	Before Market	$-0.80	-45.45%
05/09/2018	Before Market	$-0.60	33.33%
03/06/2018	Before Market	$-0.60	0.00%
11/08/2017	After Market	$-0.90	-100.00%
08/09/2017	Before Market	$-0.70	-100.00%
05/10/2017	Before Market	$-0.50	44.44%
03/16/2017	Before Market	$-1.30	-18.18%
11/09/2016	Before Market	$-0.70	30.00%
08/08/2016	After Market	$-1.10	-37.50%
05/09/2016	Before Market	$-0.90	-20.00%
03/08/2016	After Market	$7.70	13.24%
11/10/2015	After Market	$-0.40	50.00%
08/11/2015	Before Market	$-0.50	37.50%
05/07/2015	After Market	$-0.60	25.00%
03/12/2015	Before Market	$-0.90	-125.00%
11/10/2014	After Market	$-0.90	-100.00%
08/07/2014	---	$-0.70	0.00%
05/08/2014	---	$-0.80	-86.05%
03/13/2014	---	$-1.20	-275.00%
11/07/2013	---	$-0.60	25.00%
08/08/2013	---	$-0.70	-40.00%
05/09/2013	---	$-0.50	23.08%
02/28/2013	---	$-1.10	-57.14%
11/07/2012	---	$-0.60	50.00%
08/05/2012	---	$1	225.00%
05/09/2012	---	$-0.70	12.50%
02/27/2012	---	$-1	0.00%
11/07/2011	---	$-1	13.04%
08/08/2011	---	$-1.60	-33.33%
05/04/2011	---	$-0.60	3.23%
02/23/2011	---	$-1.10	-77.42%
11/08/2010	---	$-0.30	71.70%
08/05/2010	---	$-1.20	-42.86%
05/10/2010	---	$-1	2.91%
02/26/2010	---	$-1.90	-265.22%
11/09/2009	---	$-0.80	-14.29%
08/03/2009	---	$-0.70	12.50%
05/11/2009	---	$-0.70	12.50%
03/06/2009	---	$-0.90	5.26%
11/10/2008	---	$-0.90	-28.57%
09/03/2008	---	$-0.56	---
05/28/2008	---	$-0.67	---
03/17/2008	---	$-0.70	-40.00%
11/28/2007	---	$-0.72	---

More About Protalix Biotherapeutics Inc

Website

https://www.protalix.com

Country

USA

Full Time Employees

213

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.

“Protalix Biotherapeutics Inc Earnings” Can Refer to the Protalix Biotherapeutics Inc Earnings Date

Some people say “Protalix Biotherapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my Protalix Biotherapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning Protalix Biotherapeutics Inc Stock on the Earnings Date

If you own Protalix Biotherapeutics Inc stock (PLX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for Protalix Biotherapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading Protalix Biotherapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Learning More Protalix Biotherapeutics Inc Earnings

You can contact us any time if you would like to ask questions about Protalix Biotherapeutics Inc earnings or anything else related to the stock market.